Chronic Cough Evaluation: 7 Essential Workup Steps
Clinical Practice Update — A Stepwise Primary Care Workup Algorithm for Adults
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based chronic cough evaluation in adults, stepwise workup, and identification of refractory disease
- Target Audience
- Family physicians, general practitioners, nurse practitioners, physician assistants
- Setting
- Primary care and outpatient family medicine
- Source Evidence
- •CHEST Expert Cough Panel — Classification and Management of Cough in Adults (Irwin et al., 2018)
- •ERS Guidelines on the Diagnosis and Treatment of Chronic Cough (Morice et al., 2020)
- •COUGH-1 and COUGH-2 — Gefapixant for Refractory Chronic Cough (McGarvey et al., Lancet 2022)
- •GINA Global Strategy for Asthma Management and Prevention (2024 Update)
Key Clinical Takeaways
Effective chronic cough evaluation in primary care rests on three actions: defining cough duration correctly, ruling out red-flag pathology with a structured first visit, and running sequential empiric trials for the three most common causes — upper airway cough syndrome (UACS), cough-variant asthma, and gastro-oesophageal reflux. A minority of patients will persist despite thorough chronic cough evaluation; that group requires a different framework that recognises cough hypersensitivity syndrome. The rules below distil current CHEST and ERS guidance into a chronic cough evaluation you can run across 2–3 appointments.
- 1Define cough by duration: acute (<3 weeks), subacute (3–8 weeks), chronic (>8 weeks) — different durations drive different workup → Definitions
- 2Screen for red flags at every initial visit: haemoptysis, weight loss, fever, dyspnoea, occupational exposure, or abnormal imaging → Red Flags
- 3Order a chest X-ray and review medication list — discontinue any ACE inhibitor and reassess after 4 weeks → Initial Workup
- 4Treat the diagnostic triad sequentially: UACS, cough-variant asthma, and reflux cover the majority of non-smokers with a normal X-ray → Diagnostic Triad
- 5Give each empiric trial at least 4–8 weeks at adequate dose before declaring failure — premature switching is a common primary care error → Empiric Trials
- 6Refer for specialist evaluation after failed stepwise workup or if red flags emerge — do not keep re-trying the same empirics → Referral
- 7Recognise refractory chronic cough as a distinct entity — speech pathology therapy and gefapixant are emerging options → Refractory Cough
Definitions and the First Visit: Starting the Chronic Cough Evaluation
The duration of cough determines the likely cause. Acute cough (<3 weeks) is almost always infectious, subacute cough (3–8 weeks) is most often post-infectious, and chronic cough (>8 weeks) requires structured evaluation. Anchor the first visit around three tasks: confirm duration, screen for red flags, and obtain baseline investigations before any empiric therapy.
Classify cough by duration at the first visit: under 3 weeks is acute, 3–8 weeks is subacute, and over 8 weeks is chronic. Full chronic cough evaluation starts at the 8-week mark — before that, subacute post-infectious cough is the most likely diagnosis and usually resolves without intervention.
Strong Rec High Evidence CHEST 2018 ERS 2020Screen for red flags at the first visit: haemoptysis, unintentional weight loss, persistent fever, progressive dyspnoea, dysphagia, hoarseness over 3 weeks, heavy smoking history, occupational exposure (asbestos, silica), or any abnormal imaging. Any red flag takes the patient out of the standard empiric pathway and into targeted investigation.
Strong Rec High Evidence CHEST 2018Order a chest X-ray for every adult with chronic cough, review the full medication list for cough-inducing agents (especially ACE inhibitors), and document smoking status. If on an ACE inhibitor, switch to an angiotensin-receptor blocker and reassess at 4 weeks before starting any other investigation.
Strong Rec High Evidence CHEST 2018 ERS 2020Offer smoking cessation to every smoker presenting with cough. Chronic cough in a current smoker is most likely smoking-related chronic bronchitis; empiric trials for other causes rarely succeed until smoking has stopped.
Strong Rec High Evidence CHEST 2018Red Flags That Change the Workup
| Red Flag | Concerning Differential | Immediate Next Step | Why It Changes Management |
|---|---|---|---|
| Haemoptysis | Malignancy, TB, bronchiectasis, PE | CT chest + specialist referral | Empiric pathway delays cancer diagnosis |
| Unintentional weight loss | Malignancy, TB, chronic infection | CT chest; consider TB screen | Systemic feature not explained by airway causes |
| Persistent fever | TB, endemic fungi, atypical infection | Sputum studies, TB screen, CT if X-ray negative | Infection transmission risk; different treatment |
| Progressive dyspnoea | ILD, heart failure, COPD exacerbation | PFTs, BNP, echocardiography as indicated | Progressive pathology requires earlier intervention |
| Hoarseness over 3 weeks | Laryngeal malignancy, vocal cord lesion | ENT referral for laryngoscopy | Delayed diagnosis of head and neck cancer |
| Occupational exposure | Occupational asthma, pneumoconiosis, ILD | Occupational history + PFTs; specialist referral | Removal from exposure is the primary treatment |
The Diagnostic Triad in Chronic Cough Evaluation
In the non-smoking adult with a normal chest X-ray, no red flags, and not on an ACE inhibitor, three conditions account for the majority of chronic cough: upper airway cough syndrome (UACS, previously postnasal drip), cough-variant asthma (CVA) or non-asthmatic eosinophilic bronchitis (NAEB), and gastro-oesophageal reflux-related cough. A structured chronic cough evaluation tests each with a sequential or parallel empiric trial. Getting the sequence right is what turns chronic cough evaluation from open-ended into time-bound.
Trial empiric therapy for UACS first in most patients: a first-generation antihistamine-decongestant combination (e.g., chlorpheniramine with pseudoephedrine) for 2 weeks, or intranasal corticosteroid for 4–8 weeks. Second-generation antihistamines are less effective for cough-driving UACS.
Strong Rec Moderate Evidence CHEST 2018Evaluate for cough-variant asthma with spirometry (bronchodilator reversibility) and, where available, FeNO. If spirometry is normal but suspicion remains, trial an inhaled corticosteroid for 4–8 weeks — cough response supports the diagnosis. Refer for bronchial challenge testing when spirometry and ICS trial are both non-diagnostic.
Strong Rec High Evidence GINA 2024 CHEST 2018Consider reflux-related cough when typical features are present (heartburn, regurgitation, throat clearing, worse after meals or when supine). Trial a PPI at double dose for 8–12 weeks alongside lifestyle measures (weight, meal timing, head-of-bed elevation, alcohol reduction). Discontinue the PPI if there is no clear benefit.
Moderate Rec Moderate Evidence CHEST 2018 ERS 2020Do not continue empiric PPI therapy long-term if cough has not improved after an adequate trial. The evidence for empiric PPI in cough without typical reflux features is weak, and the harm profile (bone, renal, C. difficile, pneumonia) matters with indefinite use.
Against Moderate Evidence ERS 2020A Stepwise Chronic Cough Evaluation Workup
The table below organises a chronic cough evaluation by visit rather than by mechanism — the way a clinic actually runs. Each visit has a clear goal, a defined outcome, and a rule for when to move on. Every entry also notes the practical pitfalls that commonly derail the workup.
| Visit | Goal and Actions | What Confirms the Step | Common Pitfall |
|---|---|---|---|
| Visit 1 — Triage | History, exam, red-flag screen, smoking, medication review, chest X-ray | Normal X-ray, no red flags, not on ACEi | Missing the smoking or ACEi clue; skipping imaging |
| Visit 2 — UACS Trial | First-gen antihistamine/decongestant 2 wks, or intranasal steroid 4–8 wks | Clear clinical improvement in cough | Choosing a second-generation antihistamine (weaker for cough) |
| Visit 3 — Asthma Workup | Spirometry with bronchodilator, FeNO if available, ICS trial 4–8 wks | Reversibility, raised FeNO, or clear response to ICS | Diagnosing on normal spirometry alone; under-dosing ICS |
| Visit 4 — Reflux Trial | PPI double-dose 8–12 wks + lifestyle measures | Meaningful cough reduction with concurrent reflux improvement | Leaving PPI running indefinitely despite no response |
| Visit 5 — Reassess | Review all trials, repeat history, consider CT chest, specialist referral | Either a cause identified, or refractory cough diagnosis formalised | Re-trying the same empirics instead of escalating |
Investigations: When to Extend the Workup
| Test | When to Order | What It Adds | Practical Notes |
|---|---|---|---|
| Chest X-ray | Every adult with chronic cough | Rules out mass, effusion, consolidation, ILD | Normal X-ray does not exclude early malignancy in high-risk smokers |
| Spirometry | Any suspicion of asthma or COPD | Documents airflow obstruction and reversibility | Normal spirometry does not exclude cough-variant asthma |
| FeNO | Diagnosing eosinophilic airway disease | Predicts ICS response | Availability varies; useful where it exists |
| CT chest | Red flags, smoker with any abnormality, failed empiric workup | Detects bronchiectasis, malignancy, ILD, nodules | High-resolution for suspected ILD; standard for nodule/mass |
| Bronchoscopy | Suspicious CT or persistent localising signs | Direct visualisation, biopsy, BAL | Specialist-only; not indicated as screening for refractory cough |
| Oesophageal pH/impedance | Refractory cough with suspected reflux contribution | Confirms reflux-cough temporal association | Gastroenterology-led; not first-line |
Clinical Decision Pathway
A practical, question-based approach to chronic cough evaluation across 2–3 primary care visits. Work through the questions in order — each answer narrows the chronic cough evaluation to a concrete plan you can act on the same day.
Refractory Chronic Cough: When the Chronic Cough Evaluation Has No Answer
A minority of patients complete a structured chronic cough evaluation without a treatable cause being found. The ERS introduced the term refractory chronic cough (RCC) — cough persisting despite guideline-directed management — and unexplained chronic cough (UCC) — cough with no identifiable cause after thorough chronic cough evaluation. Both sit on the spectrum of cough hypersensitivity syndrome, where peripheral and central sensitisation of the cough reflex arc drives symptoms disproportionate to any identifiable trigger.
Document a formal diagnosis of refractory chronic cough after stepwise empiric trials for the UACS/asthma/GERD triad have been completed adequately and specialist assessment has excluded other pathology. Name the condition explicitly — patients often benefit from a clear diagnostic label after years of ineffective workup.
Moderate Rec Moderate Evidence ERS 2020Refer for speech pathology-led cough suppression therapy (physiotherapy and speech language therapy, PSALTI) as a non-pharmacological first-line treatment for refractory chronic cough. It teaches breathing retraining, laryngeal relaxation, and cough suppression techniques with meaningful improvement in cough frequency and quality of life.
Moderate Rec Moderate Evidence ERS 2020 CHEST 2018Consider neuromodulator trials (gabapentin, low-dose amitriptyline, or pregabalin) for refractory chronic cough under specialist supervision. Effect sizes are modest but meaningful in a condition with few options; counsel on sedation, falls risk, and dependence concerns before starting.
Conditional Rec Moderate Evidence ERS 2020Consider gefapixant (a P2X3 receptor antagonist) for refractory or unexplained chronic cough. The COUGH-1 and COUGH-2 phase 3 trials showed reductions in 24-hour cough frequency versus placebo. Taste disturbance is the main side effect and a significant reason for discontinuation; availability varies substantially between regulatory regions.
Conditional Rec High Evidence COUGH-1/2 2022Do not prescribe opioids, codeine, or dextromethorphan routinely for refractory chronic cough. Evidence for benefit is limited, side effects are significant, and the risk-benefit balance favours non-pharmacological approaches plus targeted agents.
Against Low Evidence ERS 2020Evidence in Context
Where the major guidelines on chronic cough evaluation agree, where they differ, and where the evidence is evolving — particularly around gefapixant and the cough hypersensitivity model.
Where CHEST and ERS Agree
Both societies define chronic cough by the 8-week threshold, endorse structured red-flag screening at first presentation, and recognise UACS, asthma/eosinophilic airway disease, and reflux as the dominant causes in non-smokers with a normal chest X-ray. Both agree that empiric trials should be time-limited and adequate in dose before declaring failure, and both recognise refractory chronic cough as a distinct clinical entity requiring a different therapeutic approach.
Where They Differ: PPI for Cough
CHEST 2018 allows empiric PPI trial when reflux features are present; ERS 2020 is more circumspect, citing systematic review evidence of modest benefit limited to patients with typical reflux symptoms and recommending against empiric PPI in cough without typical features. In practice, a time-limited PPI trial with an explicit stop date is a reasonable middle path in a chronic cough evaluation, provided it is discontinued when there is no response.
The Cough Hypersensitivity Model
ERS has championed a model in which chronic cough is often driven by peripheral and central sensitisation of the vagal afferent cough pathway. This paradigm reframes the condition as neurobiological rather than purely airway-mechanical and justifies neuromodulator and P2X3 antagonist trials. It also explains why cough can persist in patients who appear clinically “cured” of their underlying airway or reflux disease, and why subjective triggers such as smells, temperature, and talking dominate the clinical picture.
Gefapixant: What COUGH-1 and COUGH-2 Showed
In the phase 3 COUGH programme, gefapixant 45 mg twice daily reduced objective 24-hour cough frequency versus placebo at 12 and 24 weeks in refractory and unexplained chronic cough. Effect sizes were modest in absolute terms but meaningful in a condition with few alternatives. Taste disturbance (dysgeusia and ageusia) was the most common adverse effect and a significant driver of discontinuation. Regulatory status and availability differ between jurisdictions — approved in some regions and declined or pending in others — so verify local status before prescribing.
What We Still Don’t Know
Long-term outcomes of gefapixant beyond 24 weeks remain incompletely characterised. The comparative effectiveness of gefapixant versus speech pathology therapy has not been established in head-to-head trials. The role of second-generation P2X3 antagonists (e.g., camlipixant) is an active area of research with potentially better tolerability than gefapixant. The optimal structure of a cough hypersensitivity rehabilitation programme, and how best to integrate it in primary care, remains an open question across health systems.
References
- 1.Irwin RS, French CL, Chang AB, Altman KW; CHEST Expert Cough Panel. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196–209. doi:10.1016/j.chest.2017.10.016
- 2.Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. doi:10.1183/13993003.01136-2019
- 3.McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399(10328):909–923. doi:10.1016/S0140-6736(21)02348-5
- 4.Smith JA, Woodcock A. Chronic Cough. N Engl J Med. 2016;375(16):1544–1551. doi:10.1056/NEJMcp1414215
- 5.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2024. ginasthma.org/reports
- 6.Chamberlain Mitchell SA, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017;72(2):129–136. doi:10.1136/thoraxjnl-2016-208843
How to Read the Evidence Tags
Every recommendation in this article on chronic cough evaluation carries two tags for recommendation strength and evidence quality, plus a source tag. These are Medaptly’s own simplified interpretations designed for rapid bedside use.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | Benefit is less certain — individualise to the patient. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |